Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo®.
Back to all posts
Press Release
AlphaLogix announces market release of AlphaFlo® canine allograft
You may want to read these articles
Clinical Case: Post-Operative Management of Stifle Meniscal and Cartilage Injury in a Cutting Horse Using RenoVō®
RenoVō® vs. Alpha2EQ®: Comparing Equine Regenerative Options for Veterinary Use
As equine regenerative therapy evolves, veterinarians have more tools available to support tissue health. Two such products, RenoVō® and Alpha2EQ®, offer distinct biological compositions and clinical utility. Understanding their differences helps equine practitioners...